Literature DB >> 6089371

Cleavage of fibrinogen by human platelet calcium-activated protease.

T J Kunicki, M W Mosesson, D Pidard.   

Abstract

In lysates of washed human platelets produced by sonication or by addition of nonionic detergent, fibrinogen (Mr 340,000) was rapidly degraded, under conditions favorable to activation of the endogenous calcium-activated protease (CAP), to a core derivative (Mr 280-290,000) composed of partially degraded A alpha chains (Mr 47,000, 46,000, and 34,000) and B beta chains (Mr 56,000), and apparently intact gamma chains (Mr 53-54,000). Extensive degradation occurred within one minute at 4 degrees C, ambient temperature or at 37 degrees C, and was inhibited by leupeptin, EDTA, EGTA, or N-Ethylmaleimide, but not by soybean trypsin inhibitor, hirudin, aprotonin, benzamidine, phenylmethylsulfonyl fluoride or epsilon-aminocaproic acid. Purified plasma fibrinogen exposed to lysates containing active protease was cleaved in an identical fashion. The cleavage pattern of A alpha chains produced by this platelet protease activity is different from that produced by plasmin in vitro or that found in fibrinogen catabolites in vivo, and is unlike that produced by any cellular fibrinolytic enzyme yet described. In view of this finding, as well as the striking differential inhibitory effect of the agents cited above, we conclude that the degradation of platelet fibrinogen observed in these studies is due to direct proteolysis by platelet CAP.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6089371     DOI: 10.1016/0049-3848(84)90212-3

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  9 in total

1.  Fibrinogen cleavage by the Streptococcus pyogenes extracellular cysteine protease and generation of antibodies that inhibit enzyme proteolytic activity.

Authors:  Y V Matsuka; S Pillai; S Gubba; J M Musser; S B Olmsted
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

Review 2.  Calmodulin-binding proteins as calpain substrates.

Authors:  K K Wang; A Villalobo; B D Roufogalis
Journal:  Biochem J       Date:  1989-09-15       Impact factor: 3.857

3.  Calpain I remains intact and intracellular during platelet activation. Immunochemical measurements with monoclonal and polyclonal antibodies.

Authors:  J A Samis; G Zboril; J S Elce
Journal:  Biochem J       Date:  1987-09-01       Impact factor: 3.857

4.  High molecular weight kininogen is an inhibitor of platelet calpain.

Authors:  A H Schmaier; H Bradford; L D Silver; A Farber; C F Scott; D Schutsky; R W Colman
Journal:  J Clin Invest       Date:  1986-05       Impact factor: 14.808

5.  Fibrinogen Manchester. Detection of a heterozygous phenotype in the intraplatelet pool.

Authors:  C Southan; D A Lane; I Knight; H Ireland; J Bottomley
Journal:  Biochem J       Date:  1985-08-01       Impact factor: 3.857

6.  Proteolysis of plasma-derived factor V following its endocytosis by megakaryocytes forms the platelet-derived factor V/Va pool.

Authors:  F Ayombil; S Abdalla; P B Tracy; B A Bouchard
Journal:  J Thromb Haemost       Date:  2013-08       Impact factor: 5.824

7.  Synthesis of analogs of human platelet membrane glycoprotein IIb-IIIa complex by chicken peripheral blood thrombocytes.

Authors:  T J Kunicki; P J Newman
Journal:  Proc Natl Acad Sci U S A       Date:  1985-11       Impact factor: 11.205

8.  Characterization of proteoglycan degradation by calpain.

Authors:  K Suzuki; K Shimizu; T Hamamoto; Y Nakagawa; T Murachi; T Yamamuro
Journal:  Biochem J       Date:  1992-08-01       Impact factor: 3.857

9.  In vitro correction of the abnormal multimeric structure of von Willebrand factor in type IIa von Willebrand's disease.

Authors:  H R Gralnick; S B Williams; L P McKeown; P Maisonneuve; C Jenneau; Y Sultan; M E Rick
Journal:  Proc Natl Acad Sci U S A       Date:  1985-09       Impact factor: 11.205

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.